Wellgistics Health Announces Launch of Diabetes Drug Brenzavvy(R) to Wellgistics Pharmacy Network

Rhea-AI Summary

Wellgistics Health (NASDAQ:WGRX) began commercial launch of diabetes drug Brenzavvy to its 6,500+ independent pharmacy network on December 8, 2025. The launch targets ~33 million U.S. adults with type II diabetes and positions Brenzavvy against entrenched SGLT-2 inhibitors that reached $16.8 billion in sales in 2024, with a projected market of $28.9 billion by 2033. Wellgistics is rolling out its EinsteinRx™ AI at point-of-sale to alert pharmacists to guideline-recommended candidates (reported 11.9% current uptake) and to support pharmacist-led provider education and patient access via lower out-of-pocket cash pricing.

Positive

• 6,500+ pharmacy network targeted for launch
• Targets 33 million U.S. type II diabetics
• SGLT-2 market size: $16.8B in 2024, projected $28.9B by 2033
• EinsteinRx AI will alert pharmacists to class 1A candidates
• Reduced out-of-pocket cash price creates patient access opportunity

Negative

• Entrenched competitors with $16.8B 2024 sales present high competition
• Guideline-recommended SGLT-2 use is currently only 11.9%, limiting immediate uptake
• Commercial success depends on changing prescriber behavior via pharmacist education

Key Figures

SGLT-2 market size $16 billion Target SGLT-2 inhibitor market referenced for Brenzavvy launch

Type II diabetics US 33 million Americans diagnosed with type II diabetes targeted by launch

Pharmacies in network 6,500+ pharmacies Wellgistics Pharmacy Network coverage for Brenzavvy

2024 SGLT-2 sales $16.8 billion Global sales of Jardiance and other SGLT-2 inhibitors in 2024

2033 SGLT-2 projection $28.9 billion Projected global SGLT-2 inhibitor market by 2033

US market share 40.8% Portion of global SGLT-2 market represented by the United States

Guideline use rate 11.9% Guideline-recommended SGLT-2 use in class 1A diabetics in 2022–2023

Health systems analyzed 28 US health systems Scope of analysis on SGLT-2 inhibitor prescribing

Market Reality Check

$0.5669 Last Close

Volume Volume 720,812 vs 20-day average 1,223,095 (relative volume 0.59x) shows activity below recent norms ahead of this launch news. low

Technical Shares at $0.5669 were trading below the $1.79 200-day MA and sat 91.95% under the 52-week high, despite being 68.87% above the 52-week low.

Peers on Argus

Within pharmaceutical retailers, several peers were negative (e.g., PETS -5.71%, HKPD -4.57%, HITI -3.09%), while others rose (SSY +9.31%, SCNX +3.21%). WGRX’s -6.67% move skewed to the weaker end of this mixed group, suggesting more stock-specific pressure than a clean sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 04	Meme coin distribution	Positive	+7.0%	Announced 1-for-1 Dream Bowl 2026 meme coin to shareholders of record.
Nov 26	Sponsorship & token	Positive	+14.8%	Dream Bowl 2026 sponsorship and participation in meme coin distribution plan.
Nov 20	Earnings & update	Negative	-15.6%	Reported large Q3 2025 net loss and highlighted product and platform plans.
Nov 17	Earnings date notice	Neutral	-9.4%	Announced timing for Q3 2025 financial results and business update.
Nov 14	New distribution deal	Positive	+17.3%	Expanded distribution of GLP-1 companion medical food and antiviral combo products.

Pattern Detected

Recent news has often led to aligned price reactions, with 4 of the last 5 events moving in the intuitively expected direction.

Recent Company History

Over the last few months, Wellgistics has combined financial strain with aggressive strategic moves. The Q3 2025 report showed steep losses and a sharp negative reaction, while subsequent Dream Bowl meme coin and sponsorship announcements on Nov 26 and Dec 4 drove double‑digit gains. Distribution deals, including GLP‑1 companion products to the 6,500+ pharmacy network on Nov 14, also attracted strong interest. Today’s Brenzavvy launch builds on that same network‑driven, AI‑enabled distribution narrative.

Market Pulse Summary

This announcement details the commercial launch of Brenzavvy into a $16 billion SGLT‑2 inhibitor market serving roughly 33 million US type II diabetics via a 6,500+-pharmacy network. It emphasizes AI‑driven pharmacist prompts and education, plus a lower cash price, to expand access. In light of prior filings citing large losses and going‑concern issues, key metrics to watch include prescription uptake, pharmacy adoption of EinsteinRx, and any updates on overall liquidity and operating costs.

Key Terms

artificial intelligence technical

"Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

blockchain-enabled smart contracts technical

"into its patented blockchain-enabled smart contracts platform PharmacyChain™"

Blockchain-enabled smart contracts are self-executing agreements stored on a digital ledger that automatically enforce their terms when certain conditions are met. They function like digital vending machines: once the predefined rules are satisfied, the contract completes without needing a third party. For investors, these contracts can reduce costs, increase transparency, and ensure transactions happen reliably and instantly.

AI-generated analysis. Not financial advice.

• Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price

• Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors

• Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience

• Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders

TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the "Wellgistics Pharmacy Network") that primarily target patients in rural communities where there is often an increased incidence of diabetes. The launch is targeting the 33 million Americans who have been diagnosed with type II diabetes^[1] and whose out-of-pocket costs for SGLT-2 drugs exceed the Brenzavvy cash price.

Jardiance® and other SGLT-2 inhibitor drugs reached sales of $16.8 billion in 2024, with projected growth projected to reach $28.9 billion by 2033. The United States represents 40.8% of that market according to Grandview Research^[2]. A large scale analysis of data from 28 US health systems in 2022-2023 showed that guideline-recommended prescription of SGLT-2 inhibitors in diabetics with a class 1A recommendation is only 11.9%^[3], leading to suboptimal care for the vast majority of such patients. As the Company's proprietary EinsteinRx artificial intelligence pharmacy platform is being rolled out into the Wellgistics Pharmacy Network's point-of-sales systems, Wellgistics will alert pharmacists to patients with a likely class 1A recommendation for a SGLT-2 inhibitor, as well as the likely patient benefit from dispensing Brenzavvy vs. other SGLT-2 inhibitors in the majority of cases where such a class 1A recommendation does not exist. Once alerted, pharmacists will be able to work to rapidly educate the provider on the benefits of Brenzavvy vs. other SGLT-2 inhibitors in patients without cardiovascular disease or chronic kidney disease (CKD). Brenzavvy's competitive price point when compared with the out-of-pocket costs of Jardiance & other SGLT-2 inhibitors, provides a compelling rationale for pharmacist-driven education of providers to help optimize prescribing decisions and help improve patient access.

"By rapidly helping providers optimize therapy selection for patients without delaying dispensing timelines, pharmacists are uniquely positioned to help drive better outcomes for their patients without increasing out-of-pocket costs," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "Pharmacists are one of the most trusted sources of information about how prescription drugs will impact the health of patients, especially in rural communities. EinsteinRx is empowering these trusted healthcare professionals with the advanced technology they need to get the right drug to the right patient at the right time. With the launch of Brenzavvy through our Wellgistics Pharmacy Network, we can provide remuneration opportunities for both products and services, with the latter helping pharmacists improve their ROI by educating providers on the patient-specific advantages of Brenzavvy. We believe that this pharmacist-led provider education model will enable the blueprint for other later-generation drugs with similar product profile advantages to rapidly establish market share."

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Wellgistics Investor Relations Contact

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes

[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report

[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Wellgistics announce about Brenzavvy on December 8, 2025 for WGRX?

Wellgistics announced the commercial launch of Brenzavvy to its 6,500+ pharmacy network on December 8, 2025.

How large is the SGLT-2 market Wellgistics targets with Brenzavvy (WGRX)?

The SGLT-2 inhibitor market was $16.8 billion in 2024 and is projected to reach $28.9 billion by 2033.

How will EinsteinRx AI affect Brenzavvy dispensing in the Wellgistics network (WGRX)?

EinsteinRx will alert pharmacists at point-of-sale to likely class 1A SGLT-2 candidates and prompt pharmacist-led provider education about Brenzavvy.

What patient population is Brenzavvy targeting in the U.S. launch (WGRX)?

The launch targets approximately 33 million Americans diagnosed with type II diabetes, including uninsured and underinsured patients.

What barrier to uptake does Wellgistics note for SGLT-2 inhibitors (WGRX)?

A large analysis found guideline-recommended SGLT-2 prescribing at only 11.9% in eligible patients, indicating limited current uptake.